End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.077 AUD | 0.00% | +13.24% | +30.51% |
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 52% by 2026.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+30.51% | 45.91M | - | ||
+8.64% | 105B | B+ | ||
-0.90% | 104B | B+ | ||
+5.44% | 22.94B | B | ||
-12.25% | 22.34B | B+ | ||
-6.31% | 19.25B | A- | ||
-37.08% | 17.08B | A- | ||
-8.69% | 16.96B | B | ||
+7.59% | 14.16B | C+ | ||
+38.96% | 12.63B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- PER Stock
- Ratings Percheron Therapeutics Limited